"10.1371_journal.ppat.1003343","plos pathogens","2013-05-23T00:00:00Z","Erhard van der Vries; Koert J Stittelaar; Geert van Amerongen; Edwin J B Veldhuis Kroeze; Leon de Waal; Pieter L A Fraaij; Roland J Meesters; Theo M Luider; Bart van der Nagel; Birgit Koch; Arnold G Vulto; Martin Schutten; Albert D M E Osterhaus","Department of Virology, ErasmusMC, Rotterdam, The Netherlands; Viroclinics Biosciences B.V., Rotterdam, The Netherlands; Department of Paediatrics, ErasmusMC-Sophia, Rotterdam, The Netherlands; Department of Neurology, ErasmusMC, Rotterdam, The Netherlands; Department of Hospital Pharmacy, ErasmusMC, Rotterdam, The Netherlands","Conceived and designed the experiments: EvdV KJS AGV BK MS ADMEO. Performed the experiments: EvdV KJS GvA EJBVK LdW RJM BK. Analyzed the data: EvdV KJS GvA EJBVK LdW PLAF RJM. Contributed reagents/materials/analysis tools: RJM TML BvdN BK. Wrote the paper: EvdV KJS ADMEO.","I have read the journals policy and athors have the following conflicts: ADMEO is chief scientific officer of Viroclinics Biosciences BV. Part of this work was funded by Hoffmann-La Roche Ltd. Hoffmann-La Roche did not participate in any of the work leading to this manuscript. For the immunocompromised ferret model a patent is pending (PCT/EP2012/063497). This does not alter our adherence to all PLoS Pathogens policies on sharing data and materials.","2013","05","Erhard van der Vries","EVDV",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
